| Closed |
S2011 |
SWOG GAPTrial |
10/6/2021 |
11/15/2023 |
3% |
|
|
| Closed |
S1600 |
Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes |
2/21/2019 |
10/20/2023 |
100% |
|
|
| Closed |
S1900F |
A Randomized Phase II Study of Carboplatin and Pemetrexed With Or Without Selpercatinib In Patients With Non-Squamous RET Positive Stage IV NSCLC and Progression of Disease On Prior RET Directed Therapy |
7/25/2022 |
6/27/2023 |
0% |
|
|
| Closed |
S1800D |
LUNGMAP S1800D: Non-match Sub-Study |
2/15/2022 |
3/10/2023 |
17% |
|
|
| Closed |
S1934 |
NASSIST |
9/9/2021 |
3/1/2023 |
0% |
|
|
| Closed |
S1929 |
Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC) |
6/15/2020 |
12/15/2022 |
100% |
|
|
| Closed |
S1826 |
Phase III Study of AVD plus nivolumab or BV in pts >/= 12 years in newly diagnosed, advanced cHL |
7/19/2019 |
12/1/2022 |
100% |
|
|
| Closed |
S1614 |
Rando Prophylactic Antiviral HBV |
2/21/2019 |
11/15/2022 |
1% |
|
|
| Closed |
S1701 |
Thymic |
8/9/2018 |
9/29/2022 |
32% |
|
|
| Closed |
S1801 |
Ph II Ramdomization for Clinically Detectable Stage III-IV High-risk Melanoma |
12/6/2018 |
5/5/2022 |
100% |
|
|
| Closed |
S1613 |
RPh II Pertuzumab+Trastuzumab vs CETIRI mCRC w/HER2 amp |
10/9/2017 |
12/31/2021 |
42% |
|
|
| Closed |
S1318 |
PII Blinatumomab/POMP for Elderly Ph-Neg ALL |
1/12/2015 |
9/29/2021 |
98% |
|
|
| Closed |
S1815 |
Phase III Randomized for advanced biliary tract cancers |
12/3/2018 |
2/15/2021 |
100% |
|
|
| Closed |
S1900C |
LUNGMAP S1900C: STK11 - Talazoparib Plus Avelumab |
1/16/2020 |
12/18/2020 |
100% |
|
|
| Closed |
S1602 |
BCG Strain Differences and BCG vaccination in High-Grade Non-Muscle Invasive Bladder Cancer |
2/7/2017 |
12/15/2020 |
100% |
|
|
| Closed |
S1800A |
LUNGMAP S1800A: Non-Match Immunotherapy Combination Sub-Study |
5/17/2019 |
11/16/2020 |
100% |
|
|
| Closed |
S1607 |
T-VEC + Pembro in Adv Melanoma follow prog on PD-1 Inhibitor |
10/2/2017 |
11/1/2020 |
67% |
|
|
| Closed |
S1619 |
Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab |
11/3/2017 |
5/1/2020 |
100% |
|
|
| Closed |
S1400F |
Lung-MAP S1400F: Non-Match-MEDI4736 and Tremelimumab |
10/2/2017 |
3/24/2020 |
51% |
|
|
| Closed |
S1702 |
Ph II AL amyloidosis isatuximab |
3/8/2018 |
9/30/2019 |
100% |
|
|
